デフォルト表紙
市場調査レポート
商品コード
1375907

膣炎治療薬の市場規模、シェア、動向分析レポート:疾患タイプ別、製品別、地域別、セグメント別予測、2023年~2030年

Vaginitis Therapeutics Market Size, Share & Trends Analysis Report By Disease Type (Anti-fungal, Anti-bacterial, Hormone), By Product (OTC, Prescription), By Region, And Segment Forecasts, 2023 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 75 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
膣炎治療薬の市場規模、シェア、動向分析レポート:疾患タイプ別、製品別、地域別、セグメント別予測、2023年~2030年
出版日: 2023年10月10日
発行: Grand View Research
ページ情報: 英文 75 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

膣炎治療薬市場の成長と動向:

Grand View Research, Inc.の最新レポートによると、世界の膣炎治療薬市場規模は、2023年から2030年にかけて8.3%のCAGRを記録し、2030年までに60億米ドルに達する見込みです。

女性の意識レベルを高めるための政府や非政府機関による支援的な取り組みが、膣炎治療薬の需要を促進しています。アルコール消費量の増加も、これらの薬剤の採用に拍車をかけていると推定されます。米国では約530万人の女性が、健康と一般的な幸福に関連するリスクにさらされています。

さらに、膣炎治療薬の研究開発活動の高まりは、市場の成長を加速させると予測されています。米国国立アレルギー感染症研究所(NIAID)が資金を提供した調査により、イースト菌の発生行動に関する様々な重要なデータが発見され、イースト菌感染症の新しい治療法が生まれる可能性があります。さらに、主要企業による新薬のイントロダクションが市場成長を促進すると期待されています。例えば、2017年9月、Symbiomix Therapeutics社は細菌性膣炎治療薬Solosec(secnidazole)のFDA承認を取得しました。

膣炎治療薬市場レポートハイライト

  • 抗菌薬セグメントは、幅広い製品群の利用可能性と細菌性膣炎の症例数の増加により、2022年の売上高シェア37.9%で膣炎治療薬市場を牽引。
  • ホルモンは、パイプライン製品の存在と製品採用の増加により、予測期間のCAGRが8.4%となり、有利な成長が見込まれます。
  • 処方薬セグメントは、処方薬の高い有効性と安全性、重症で再発を繰り返す膣炎に対する幅広い薬剤の利用可能性により、2022年に51.2%の最大の売上シェアで市場をリードしました。
  • 市販薬セグメントは、軽度の膣炎治療に対するFDA承認の増加により、今後数年間はCAGR 8.7%で拡大すると予想されます。
  • 北米は、質の高いヘルスケアサービスと膣炎患者の増加により、2022年の売上高で38.3%のシェアを占めました。
  • アジア太平洋は、予測期間中のCAGRが約9.5%で、最も速い成長を示すと予測されています。この成長の背景には、政府の積極的な取り組みと可処分所得の上昇に加え、対象人口が多いことがあります。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 膣炎治療薬市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 膣炎治療薬市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 膣炎治療薬市場:疾患タイプの推定・動向分析

  • 膣炎治療薬市場:疾患の種類に関する重要なポイント
  • 膣炎治療薬市場:疾患タイプの動向と市場シェア分析、2022年および2030年
  • 抗真菌
  • 抗菌
  • ホルモン

第5章 膣炎治療薬市場:製品推定・動向分析

  • 膣炎治療薬市場:製品の重要なポイント
  • 膣炎治療薬市場:製品動向と市場シェア分析、2022年および2030年
  • 店頭
  • 処方箋

第6章 膣炎治療薬市場:地域推定・動向分析

  • 地域別の見通し
  • 地域別の膣炎治療薬市場:重要なポイント
  • 北米
    • 市場推計・予測、2018~2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Symbiomix Therapeutics LLC.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Bayer AG
    • Janssen Pharmaceuticals Inc.
    • Lupin Pharmaceuticals Inc.
    • Lumavita AG
    • Mission Pharmacal Company
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 3 North America vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 6 U.S. vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 7 Canada vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 8 Canada vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 9 Europe vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 10 Europe vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 11 Europe vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 13 Germany vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 14 UK vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 15 UK vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 16 France vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 17 France vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 18 Italy vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 19 Italy vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 20 Spain vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 21 Spain vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 22 Sweden vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 23 Sweden vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 24 Norway vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 25 Norway vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 26 Denmark vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 27 Denmark vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 31 China vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 32 China vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 33 Japan vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 34 Japan vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 35 India vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 36 India vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 37 Australia vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 38 Australia vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 39 Thailand vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 40 Thailand vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 41 South Korea vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 42 South Korea vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 43 Latin America vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 44 Latin America vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 45 Latin America vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 47 Brazil vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 48 Mexico vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 49 Mexico vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 50 Argentina vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 51 Argentina vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 56 South Africa vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 59 UAE vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 60 UAE vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 61 Kuwait vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Vaginitis Therapeutics: Market outlook
  • Fig. 9 Vaginitis Therapeutics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Vaginitis Therapeutics market driver impact
  • Fig. 15 Vaginitis Therapeutics market restraint impact
  • Fig. 16 Vaginitis Therapeutics market strategic initiatives analysis
  • Fig. 17 Vaginitis Therapeutics market: Disease type movement analysis
  • Fig. 18 Vaginitis Therapeutics market: Disease type outlook and key takeaways
  • Fig. 19 Anti-fungal market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 20 Anti-bacterial market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 21 Hormone market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 22 Vaginitis Therapeutics market: Product movement analysis
  • Fig. 23 Vaginitis Therapeutics market: Product outlook and key takeaways
  • Fig. 24 Over-the-counter market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 25 Prescription (Rx) market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 26 Global Vaginitis Therapeutics market: Regional movement analysis
  • Fig. 27 Global Vaginitis Therapeutics market: Regional outlook and key takeaways
  • Fig. 28 North America market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 29 U.S. market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 30 Canada market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 31 Europe market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 32 UK market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 33 Germany market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 34 France market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 35 Italy market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 36 Spain market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 37 Sweden market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 38 Norway market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 39 Denmark market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 40 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 41 Japan market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 42 China market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 43 India market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 44 Australia market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 45 Thailand market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 46 South Korea market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 47 Latin America market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 48 Brazil market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 50 Argentina market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 51 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 52 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 53 South Africa market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 54 UAE market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 55 Kuwait market estimates and forecasts, 2018 - 2030 (USD Billion)
目次
Product Code: GVR-2-68038-604-2

Vaginitis Therapeutics Market Growth & Trends:

The global vaginitis therapeutics market size is expected to reach USD 6.0 billion by 2030, registering a CAGR of 8.3% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Supportive initiatives by government and non-government agencies to increase awareness level among women is driving the demand for vaginitis drugs. Increased consumption of alcohol is also estimated to fuel the adoption of these drugs. Around 5.3 million women in the U.S. are at risk related to health and general well-being.

Furthermore, rising R&D activities for vaginitis therapeutics is anticipated to accelerate the market growth. National Institute of Allergy and Infectious Diseases (NIAID)-funded research has discovered various important data about yeast generative behavior, which could result in new way of treatment for yeast infections. In addition, introduction of new drugs by key companies is expected to propel the market growth. For instance, in September 2017, Symbiomix Therapeutics received FDA approval for Solosec (secnidazole) for the treatment of bacterial vaginosis.

Vaginitis Therapeutics Market Report Highlights:

  • Anti-bacterial segment led the market for vaginitis therapeutics with a revenue share of 37.9% in 2022 owing to the availability of a wide product range and higher number of cases of bacterial vaginosis disease
  • Hormone is expected to witness lucrative growth with a CAGR of 8.4% over the forecast period due to the presence of pipeline products and rising adoption of products
  • The prescription segment led the market with the largest revenue share of 51.2% in 2022, owing to the higher efficacy and safety of prescribed drugs and availability of a wide range of drugs for severe and recurring vaginitis
  • Over the counter segment is expected to expand at a CAGR of 8.7% in the coming years due to increasing number of FDA approvals for the treatment of mild vaginitis
  • North America dominated the market with a revenue share of 38.3% in 2022, in terms of revenue, owing to of high-quality healthcare services and increasing cases of vaginitis
  • Asia Pacific is estimated to witness the fastest growth, with a CAGR of around 9.5% over the forecast period. This growth is attributed to favorable government initiatives and rising disposable income along with the presence of a large target population base.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Disease Type
    • 1.1.2. Product
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease Type outlook
    • 2.2.2. Product outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Vaginitis Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Vaginitis Therapeutics Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Vaginitis Therapeutics Market: Disease Type Estimates & Trend Analysis

  • 4.1. Vaginitis Therapeutics Market: Disease Type Key Takeaways
  • 4.2. Vaginitis Therapeutics Market: Disease Type Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Anti-fungal
    • 4.3.1. Anti-fungal market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Anti-bacterial
    • 4.4.1. Anti-bacterial market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Hormone
    • 4.5.1. Hormone market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Vaginitis Therapeutics Market: Product Estimates & Trend Analysis

  • 5.1. Vaginitis Therapeutics Market: Product Key Takeaways
  • 5.2. Vaginitis Therapeutics Market: Product Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Over-the-counter
    • 5.3.1. Over-the-counter market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Prescription
    • 5.4.1. Prescription market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Vaginitis Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Vaginitis Therapeutics Market by Region: Key Takeaways
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Denmark
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Norway
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Symbiomix Therapeutics LLC.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Merck & Co., Inc.
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Pfizer Inc.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Novartis AG
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Teva Pharmaceutical Industries Ltd.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Bayer AG
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Janssen Pharmaceuticals Inc.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Lupin Pharmaceuticals Inc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Lumavita AG
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Mission Pharmacal Company
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives